Journal article
Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
Journal of thrombosis and haemostasis, Vol.18(2), pp.341-351
02/01/2020
DOI: 10.1111/jth.14660
PMCID: PMC7027501
PMID: 31618804
Abstract
BackgroundThe current standard of care for patients with hemophilia A is regular prophylaxis with factor VIII (FVIII) administered intravenously. Interest in subcutaneous (s.c.) administration, to potentially increase convenience, reduce the treatment burden and improve compliance, is increasing.
ObjectivesEvaluate the pharmacokinetics (PK), immunogenicity, safety, and preliminary efficacy of s.c. administration of turoctocog alfa pegol (s.c. N8-GP) in adult or adolescent previously treated patients (PTPs) with severe hemophilia A (alleviate 1; NCT02994407).
Patients/MethodsIn part A, 24 PTPs received a single dose of s.c. N8-GP (12.5, 25, 50, or 100 IU/kg) with 6 patients per cohort. PK modelling of data from part A supported a suitable dose for part B. Part B comprised a multiple dose trial in 26 PTPs; patients <60 kg received 2000 IU and patients >= 60 kg received 4000 IU s.c. N8-GP daily for 3 months.
ResultsSingle-dose s.c. N8-GP supported dose linearity. Daily prophylaxis with s.c. N8-GP appeared well tolerated and efficacious, achieving a mean trough FVIII activity close to 10% at steady state. Five patients developed anti-N8-GP binding antibodies after 42 to 91 exposure days, one of whom developed an inhibitor to FVIII. Anti-N8-GP antibody appearance was associated with a decline in FVIII plasma activity in four of the five patients. Five patients reported a total of nine treatment-requiring bleeding episodes during prophylaxis.
ConclusionsSubcutaneous administration of N8-GP is associated with a high incidence of antibodies in PTPs with severe hemophilia A. Further clinical development of s.c. N8-GP has been suspended.
Details
- Title: Subtitle
- Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1)
- Creators
- Robert Klamroth - Klinikum im FriedrichshainClemens Feistritzer - Innsbruck Medical UniversityUte Friedrich - Novo NordiskSteven R. Lentz - Roy J. and Lucille A. Carver College of MedicineKirsten Reichwald - Novo NordiskMarek Zak - Novo NordiskPratima Chowdary - Royal Free London NHS Foundation Trust
- Resource Type
- Journal article
- Publication Details
- Journal of thrombosis and haemostasis, Vol.18(2), pp.341-351
- Publisher
- Wiley
- DOI
- 10.1111/jth.14660
- PMID
- 31618804
- PMCID
- PMC7027501
- ISSN
- 1538-7933
- eISSN
- 1538-7836
- Number of pages
- 11
- Grant note
- Novo Nordisk (Bagsvaerd, Denmark) - Novo Nordisk; Novo Nordisk
- Language
- English
- Date published
- 02/01/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359924902771
Metrics
10 Record Views